首页> 外文期刊>BJU international >Tumour thrombus consistency: A new tool to stage patients with pT3 renal cell carcinoma (RCC) with venous tumour thrombus?
【24h】

Tumour thrombus consistency: A new tool to stage patients with pT3 renal cell carcinoma (RCC) with venous tumour thrombus?

机译:肿瘤血栓的一致性:分期治疗pT3肾细胞癌(RCC)静脉肿瘤血栓的新工具?

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Despite the further refinements included in the newly released seventh edition, the pT3 substages identified by the 2010 American Joint Committee on Cancer-Union Internationale Contre le Cancer TNM classification present overlapping prognoses and include patients with heterogeneous outcomes. Novara et al. [1] showed that 5-year cancer-specific survival (CSS) for the pT3a subcategory was 75% in patients with renal vein invasion only and 32.4% in patients with concomitant renal vein and perirenal fat invasion. Similarly, CSS probability for the pT3b subcategory was 65.9% in patients with infra-diaphragmatic vena caval thrombus only and 36.5% in patients with concomitant invasion of the perirenal fat. In addition, the Mayo Clinic validation of the 2010 TNM classification showed that pT3b and pT3c disease behaved similarly to each other [2] and patients with pT3a disease and concomitant perirenal fat invasion and renal vein thrombus had a markedly lower 10-year CSS than those with level 0 renal vein thrombus alone.
机译:尽管在新发布的第七版中进行了进一步的改进,但由美国国际癌症协会联合委员会控制的TNM分类2010年确定的pT3子集的预后相互重叠,并且包括预后不一的患者。 Novara等。 [1]表明,pT3a子类别的5年癌症特异性生存率(CSS)仅在肾静脉浸润患者中为75%,在伴发肾静脉和肾周脂肪浸润中为32.4%。同样,pT3b子类别的CSS概率仅在dia下腔静脉血栓患者中为65.9%,在伴有肾周脂肪浸润的患者中为36.5%。此外,Mayo Clinic对2010年TNM分类的验证表明pT3b和pT3c疾病的表现相似[2],患有pT3a疾病,并发肾周脂肪浸润和肾静脉血栓的患者的10年CSS明显低于那些单独有0级肾静脉血栓。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号